SLNO
SOLENO THERAPEUTICS INC
No data for this timeframe.
Vol
Analyst ConsensusSell (0%)
Inst. Holders6 funds
Inst. Value$559.8M
Inst. Activity3 buys / 0 sells
Insider Activity0B / 2S
Insider Net $-$273.9K
SEC Reports8
Recent Activity
May 28, 2026
SEC
Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and suspend reporting obliga
15-12G — Impact 8/10
May 28, 2026
SEC
Soleno Therapeutics' shelf registration statement on Form S-3 (File No. 333-275120) was declared effective by the SEC on
EFFECT — Impact 5/10
May 18, 2026
SEC
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.00 per share in cash
8-K, 25-NSE — Impact 8/10
May 18, 2026
Insider
Anish Bhatnagar sold 583,656 shares
CHIEF EXECUTIVE OFFICER @ $0.00 ($0.00)
May 18, 2026
Insider
Anish Bhatnagar sold 22,452 shares
CHIEF EXECUTIVE OFFICER @ $0.00 ($0.00)
May 18, 2026
Insider
Bir Dawn Carter sold 16,991 shares
Director @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — ADD
287,639 shares ($13.3M)
Inst.
BANK OF AMERICA CORP — ADD
208,595 shares ($9.7M)
Price Targets
$53.00
-0.0% upside
Hold
Current $53.01
Low $53.00
Median $53.00
High $53.00
5 analysts
$53.00
$53.00
Analyst Ratings
0Strong Buy
0Buy
13Hold
1Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | DOWNGRADE | Overweight → Equal-Weight |
| Apr 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Apr 7, 2026 | TD Cowen | DOWNGRADE | Buy → Hold |
| Apr 7, 2026 | Wolfe Research | DOWNGRADE | Outperform → Peer Perform |
| Apr 6, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.93 | $0.78 — $1.26 | 1138% YoY | 8 |
| Next Q | $1.06 | $0.78 — $1.55 | 126% YoY | 8 |
| Current FY | $3.89 ▼ -1.4% | $2.69 — $5.55 | 898% YoY | 8 |
| Next FY | $6.06 ▼ -3.6% | $3.61 — $9.92 | 56% YoY | 7 |
Latest Reports
BEARISH
15-12G
8/10
Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and suspend reporting obliga
May 28, 2026
BEARISH
EFFECT
5/10
Soleno Therapeutics' shelf registration statement on Form S-3 (File No. 333-275120) was declared effective by the SEC on
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $374.1M | DOUBLED |
| VANGUARD GROUP INC | $141.7M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $18.6M | ADD |
| MORGAN STANLEY | $13.3M | ADD |
| BANK OF AMERICA CORP | $9.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Anish Bhatnagar | D | $0.00 |
| May 18, 2026 | Anish Bhatnagar | D | $0.00 |
| May 18, 2026 | Bir Dawn | D | $0.00 |
| May 18, 2026 | Fulk Jennifer | D | $0.00 |
| May 18, 2026 | Fulk Jennifer | D | $0.00 |
6 institutional holders with $559.8M total value (12,089,728 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, CHARLES. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,079,304 | $374.1M | 66.8% | DOUBLED +139.7% |
| 2 | VANGUARD GROUP INC | 3,060,361 | $141.7M | 25.3% | ADD +33.3% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 401,186 | $18.6M | 3.3% | ADD +31.4% |
| 4 | MORGAN STANLEY | 287,639 | $13.3M | 2.4% | ADD +73.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 208,595 | $9.7M | 1.7% | ADD +28.7% |
| 6 | WELLS FARGO & COMPANY/MN | 52,643 | $2.4M | 0.4% | ADD +72.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 165,845 | 287,639 | +73.4% | $13.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 162,098 | 208,595 | +28.7% | $9.7M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 30,480 | 52,643 | +72.7% | $2.4M | 2025-Q4 |
| FMR LLC | DOUBLED | 3,337,858 | 7,999,682 | +139.7% | $540.8M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 296,262 | 389,356 | +31.4% | $26.3M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 440,054 | 165,845 | -62.3% | $11.2M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 238,643 | 162,098 | -32.1% | $11.0M | 2025-Q3 |
| UBS Group AG | ADD | 105,996 | 158,308 | +49.4% | $10.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 21,160 | 30,480 | +44.0% | $2.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 45,200 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | ADD | 2,233,473 | 3,337,858 | +49.4% | $279.6M | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 1,866,326 | 2,487,832 | +33.3% | $208.4M | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 212,359 | 440,054 | +107.2% | $36.9M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 213,984 | 296,262 | +38.5% | $24.8M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 465,059 | 238,643 | -48.7% | $20.0M | 2025-Q2 |
| UBS Group AG | ADD | 57,477 | 105,996 | +84.4% | $8.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 45,200 | — | $3.8M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 12,473 | 21,160 | +69.6% | $1.8M | 2025-Q2 |
| FMR LLC | DOUBLED | 813,027 | 2,233,473 | +174.7% | $159.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 1,302,810 | 2,076,044 | +59.4% | $148.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 64,840 | 1,302,810 | +1909.3% | $58.6M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 73,981 | 210,237 | +184.2% | $9.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 8,937 | 12,547 | +40.4% | $564.0K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 192,597 | — | $9.7M | 2024-Q3 |
12 unique insiders with 2 transactions. Net insider value: -$273.9K ($0.00 bought, $273.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | D | 583,656 | $0.00 | $0.00 |
| May 18, 2026 | Anish Bhatnagar | CHIEF EXECUTIVE OFFICER | D | 22,452 | $0.00 | $0.00 |
| May 18, 2026 | Bir Dawn Carter | Director | D | 16,991 | $0.00 | $0.00 |
| May 18, 2026 | Fulk Jennifer | CHIEF FINANCIAL OFFICER | D | 67,660 | $0.00 | $0.00 |
| May 18, 2026 | Fulk Jennifer | CHIEF FINANCIAL OFFICER | D | 39,200 | $0.00 | $0.00 |
| May 18, 2026 | Hahn Mark W | Director | D | 10,046 | $0.00 | $0.00 |
| May 18, 2026 | Huang Michael F. | Sr. VP of Clinical Development | D | 39,823 | $0.00 | $0.00 |
| May 18, 2026 | Huang Michael F. | Sr. VP of Clinical Development | D | 110,000 | $0.00 | $0.00 |
| May 18, 2026 | Joshi Manher | Chief Development Officer | D | 20,171 | $0.00 | $0.00 |
| May 18, 2026 | Joshi Manher | Chief Development Officer | D | 72,321 | $0.00 | $0.00 |
| May 18, 2026 | Manning Meredith | Chief Commercial Officer | D | 64,507 | $0.00 | $0.00 |
| May 18, 2026 | Manning Meredith | Chief Commercial Officer | D | 91,000 | $0.00 | $0.00 |
| May 18, 2026 | Manning Meredith | Chief Commercial Officer | D | 29,200 | $0.00 | $0.00 |
| May 18, 2026 | Norrett Kevin | Chief Business Officer | D | 17,786 | $0.00 | $0.00 |
| May 18, 2026 | Norrett Kevin | Chief Business Officer | D | 64,286 | $0.00 | $0.00 |
| May 18, 2026 | Pauls Matthew | Director | D | 10,491 | $0.00 | $0.00 |
| May 18, 2026 | Pauls Matthew | Director | D | 9,063 | $0.00 | $0.00 |
| May 18, 2026 | Sinclair Andrew | Director | D | 10,491 | $0.00 | $0.00 |
| May 18, 2026 | Sinclair Andrew | Director | D | 1,333 | $0.00 | $0.00 |
| May 18, 2026 | Volck Birgitte | Director | D | 17,536 | $0.00 | $0.00 |
| May 18, 2026 | Volck Birgitte | Director | D | 1,333 | $0.00 | $0.00 |
| May 18, 2026 | Yen Kristen | SEE REMARKS | D | 37,639 | $0.00 | $0.00 |
| May 18, 2026 | Yen Kristen | SEE REMARKS | D | 1,741 | $0.00 | $0.00 |
| Mar 27, 2026 | Huang Michael F. | Sr. VP of Clinical Development | SELL | 4,256 | $30.04 | $127.8K |
| Mar 27, 2026 | Manning Meredith | Chief Commercial Officer | SELL | 4,864 | $30.04 | $146.1K |
| Mar 2, 2026 | Fulk Jennifer | CHIEF FINANCIAL OFFICER | M | 67,660 | $0.00 | $0.00 |
| Mar 2, 2026 | Fulk Jennifer | CHIEF FINANCIAL OFFICER | A | 39,200 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 3 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 6.3/10.
BEARISH
15-12G
8/10
Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and susp
May 28, 2026
BEARISH
EFFECT
5/10
Soleno Therapeutics' shelf registration statement on Form S-3 (File No. 333-275120) was declared eff
May 28, 2026
BULLISH
8-K, 25-NSE
8/10
Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.
May 18, 2026
BEARISH
8-K
7/10
Soleno Therapeutics has voluntarily withdrawn its marketing authorization application (MAA) for VIOK
Apr 7, 2026
BULLISH
8-K
8/10
Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, representing a
Apr 6, 2026
NEUTRAL
CLUSTER
3/10
Analysis based on filing metadata only — document content was unavailable. Two insiders at Soleno Th
Apr 1, 2026
NEUTRAL
8-K
3/10
Soleno Therapeutics announced the retirement of CFO James Mackaness and the appointment of Jennifer
Feb 26, 2026
BULLISH
8-K
8/10
Soleno Therapeutics reported strong first-year commercial results for VYKAT XR, generating $190.4 mi
Feb 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Sell (0% buy). Based on 16 analysts: 0 strong buy, 0 buy, 13 hold, 1 sell, 2 strong sell.
Analyst Price Targets
$53.00 mean target
-0.0% upside
Hold (3.00)
$53.00 Low
$53.00 High
| Metric | Value |
|---|---|
| Current Price | $53.01 |
| Target Low | $53.00 |
| Target Mean | $53.00 |
| Target Median | $53.00 |
| Target High | $53.00 |
| # Analysts | 5 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.93 | $0.78 | $1.26 | 1137.5% | -0.4% | 0↑ 3↓ | $0.1B | 242.4% | 8 |
| Next Q 2026-09-30 |
$1.06 | $0.78 | $1.55 | 125.5% | +0.0% | 0↑ 4↓ | $0.1B | 86.1% | 8 |
| Current FY 2026-12-31 |
$3.89 | $2.69 | $5.55 | 897.8% | -1.4% | 0↑ 4↓ | $0.5B | 143.9% | 8 |
| Next FY 2027-12-31 |
$6.06 | $3.61 | $9.92 | 55.6% | -3.6% | 0↑ 4↓ | $0.7B | 44.4% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.934 | |
| 7d ago | $0.938 | -0.004 |
| 30d ago | $0.938 | -0.004 |
| 60d ago | $0.939 | -0.005 |
| 90d ago | $0.980 | -0.046 |
6 analyst firms have rated this stock: 0 upgrades, 5 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Apr 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Apr 7, 2026 | TD Cowen | DOWNGRADE | Buy | Hold |
| Apr 7, 2026 | Wolfe Research | DOWNGRADE | Outperform | Peer Perform |
| Apr 6, 2026 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Mar 18, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 26, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 13 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 13 | 1 | 2 | 0% | |
| Apr 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
short_interest
FTD: SLNO — 34,067 shares ($1.8M) failed to deliver
Settlement: 20260514, Price: $52.95, FTD Value: $1,803,847.65, SOLENO THERAPEUTICS INC COM PA
May 13, 2026
short_interest
FTD: SLNO — 9,562 shares ($0.5M) failed to deliver
Settlement: 20260513, Price: $52.93, FTD Value: $506,116.66, SOLENO THERAPEUTICS INC COM PA
May 12, 2026
earnings_calendar
SLNO Q1 2026 Earnings Scheduled — 2026-05-12
May 5, 2026
short_volume
Short Volume: SLNO — 66.5% short (0.4M / 0.6M)
Short: 379,172 | Exempt: 0 | TRF Vol: 570,050 | Short Ratio: 66.5% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
SLNO Q1 2026 Earnings Scheduled — 2026-05-05
Apr 2, 2026
short_volume
Short Volume: SLNO — 67.8% short (1.1M / 1.6M)
Short: 1,066,396 | Exempt: 0 | TRF Vol: 1,572,379 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
short_interest
FTD: SLNO — 25,443 shares ($0.8M) failed to deliver
Settlement: 20260330, Price: $30.05, FTD Value: $764,562.15, SOLENO THERAPEUTICS INC COM PA
Mar 27, 2026
short_volume
Short Volume: SLNO — 56.1% short (0.4M / 0.8M)
Short: 420,982 | Exempt: 2,358 | TRF Vol: 751,010 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_interest
FTD: SLNO — 240,354 shares ($7.7M) failed to deliver
Settlement: 20260327, Price: $31.86, FTD Value: $7,657,678.44, SOLENO THERAPEUTICS INC COM PA
Mar 25, 2026
short_volume
Short Volume: SLNO — 74.6% short (0.4M / 0.6M)
Short: 446,740 | Exempt: 0 | TRF Vol: 598,659 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Feb 25, 2026
earnings_calendar
SLNO Q4 2025 Earnings After Market Close — 2026-02-25